Implications of Fecal Microbiota Transplantation in Modulating the Effects of Liver Cirrhosis

Implications of Fecal Microbiota Transplantation in Modulating the Effects of Liver Cirrhosis

The study aims to investigate the beneficial effects of fecal transplantation in patients diagnosed with liver cirrhosis (regardless of etiology).

Participants in the experimental group will receive fecal microbiota transplantation (FMT) from a screened healthy donor. Each patient will undergo colonoscopic delivery of a minimum of 70 grams of donor fecal material into the cecum. The study will assess outcomes by monitoring clinical status, laboratory tests, imaging results and stool analyses (including assessment of micro-RNA profiles), comparing changes from baseline and with the control group. Participants will undergo scheduled re-evaluations at approximately 1 month post-transplant (timing may vary slightly due to clinical or logistical considerations).

Inclusion Criteria:

• Diagnosis of liver cirrhosis according to current protocols.
• Conscious and cooperative adult patients.

Exclusion Criteria:

• Patients with hemodynamic and/or respiratory instability.
• Patients with contraindications for colonoscopy or fecal transplantation.
• Patients with acute or chronic infections with HIV, Tuberculosis, MDR Enterobacteria, CMV, parasites, fungi.
• Associated oncological pathology.
• Patients with other causes of severe immunodeficiencies.
• Lack of compliance with the conditions imposed by the research project.
• Patients who do not sign the informed consent.